Reports from the conference.

• Rifaximin cure reported for cryptosporidium in advanced HIV

• Analysis of hepatic events in 2NN study by CD4 entry criteria, levels differences between nevirapine and efavirenz; excess hepatic events in once-daily nevirapine arm linked to single site in Thailand

• FTC studies at EACS: reduced incidence of M184V compared to 3TC; side effect profile in clinical practice

• Paediatric studies at EACS: trends in antiretroviral use in the Madrid Cohort; life expectancy significantly increased HIV/HCV co-infected children since HAART; use of tenofovir in treatment experienced children; switching to lopinavir/r from double protease inhibitor regimen; once daily lopinavir/r, 3TC and abacavir; planned treatment interruptions in children

• Efficacy of lopinavir/r in patients with advanced HIV (CD4 <25 cells/mm3)

• Potential barriers to use of T-20: results from patient and physician interviews

• Factors associated with sexual dysfunction in HIV patients

• Decreased varicella zoster immunity in migrants from sub-Saharan Africa

• Clinical experience of switching to atazanavir in the UK’s largest clinic

• Replacing a PI with atazanavir: separating swans from ducklings?

• TMC 125: some good and bad news

• When to change a failing regimen: second-line and salvage strategies

• Antiretrovirals and other stuff!

• Heart disease in people with HIV

• Mortality trends: why people with HIV die (or don’t) today

The conference organisers have not yet published abstracts from the meeting online, although they will go online at:

AIDS Education Global information System (AEGiS.org)

http://www.aegis.org

However, webcasts of several of the presentations are included, though free registration is required, and access is not instant:

10th EUROPEAN AIDS CONFERENCE / EACS

http://www.eacs-conference2005.com

The following subjects are covered in the reports from this conference:

• Rifaximin cure reported for cryptosporidium
• Analysis of hepatic events in 2NN study
• Efficacy of lopinavir/r in patients with advanced HIV
• Potential barriers to use of T-20
• FTC studies at EACS
• Paediatric studies at EACS
• Factors associated with sexual dysfunction in HIV patients
• Decreased varicella zoster immunity in migrants from sub-Saharan Africa
• Clinical experience of switching to atazanavir
• TMC 125: some good and bad news
• Second-line and salvage strategies
• Antiretrovirals and other stuff!
• Heart disease in people with HIV
• Mortality trends: why people with HIV die (or don’t) today